All filters
Slidesets
The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
What challenges remain in viral hepatitis- Jürgen Rockstroh, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
NASH and NAFLD in HIV: same or different? - Mariana Machado, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
WHO Target 90-90-90 : Achievable for Latin America- Alejandro Afani, MD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
HIV in Latin America: 35 years later- Marcelo Wolff, MD, FACP, FIDSA
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Difficult to reach populations in Latin America- Ana Paulina Celi de la Torre, MD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
New approaches for preventing transmission- Charles Boucher, MD, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
State-of-the-art lecture on PrEP- Mauro Schechter, MD, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Proviral DNA as a Target for HIV-1 Resistance Analysis- Dr. Lara
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Transmitted Drug Resistance in HIV-Infected Treatment-Naïve Patients in Chile between 2014 and 2017- Dr. Palma
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Clinical Implications of low level viremia/ failure and resistance- Francesca Ceccherini– Silberstein, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Risk profiles for HIV transmission and HIV status in MSM versus heterosexual men populations in the South West of Colombia - Dr. Mueses-Marín
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Moving forward to 90-90-90: Analysis of a cohort of recently-diagnosed patients in a tertiary hospital in Buenos Aires, Argentina - Dr. Barletta
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Early diagnosis & testing- Susana Cabrera, MD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
High rates of retention on ART and virological suppression in a large cohort study from The Chilean AIDS Group- Dr. Beltrán
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Strategies for hepatitis C elimination- Francesca Ceccherini– Silberstein, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
HIV- hepatitis co-infected patients- Pedro Cahn, MD, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017